T
he pathogenesis of fibrosing interstitial pneumonitis is currently thought to involve an early but progressive inflammatory response and injury to parenchymal cells. This injury could derive from the inflammation, be independent of it, or even could induce an inflammatory reaction. Unfortunately, while these ideas set a useful framework within which to pursue investigation of this group of diseases, they are no more than broad brushstrokes, and certainly at this It is important in such a discussion to consider the definition of "injury." The term is employed very loosely, often encompassing phenomena that in other circumstances might be considered physiologic. Usage also tends not to discriminate between changes in cells, vessels, or the whole lung. Permeability is commonly considered to be a manifestation of injury. This concept not only can be challenged in itself (for certain forms of permeability change) but often does not distinguish endothelial from epithelial alterations. "Injury" must include both structural and functional elements, the former being easier to delineate. A strong plea can be made, therefore, to define operationally the terms injury and damage in writings on this subject. For the purposes of this discussion, cellular injury will indicate severe morphologic alteration up to and including lysis and detachment and inability to replicate.
Within the framework outlined above, mechanisms of cellular, and especially endothelial and epithelial injury would take on new relevance (Fig 1) , Certainly, externally administered materials that promote pulmonary fibrotic reaction such as bleomycin and paraquat are cell toxins.
Because they are thought to act via oxygen dependent processes, great emphasis has been placed on oxygen-radical mediated cellular toxicity. In experimental animals, local administration of tetradecanol phorbol myristate (TPA or PMA) produces fibrosis in the pulmonary parenchyma and pleural cavity. 3, 4 Since this agent is known to be an extremely potent stimulant to oxygen radical production (presumably by its activation of protein kinase C), coupled with some oxygen radical scavenger data, involvement of these oxygenderived toxins in fibrotic processes has been inferred. Once again, this brings up the question of a role for the inflammatory process in lung cell injury because infiltrating inflammatory cells are prolific producers of oxygen radicals.
In this discussion, it is not crucial to enter into the controversy about the possible fibrogenic or antifibrogenic role of the polymorphonuclear neutrophil leukocyte in pulmonary fibrosis. More broadly, it seems reasonable to sug- although other endogenous agents, including the phospholipid platelet activating factor, can also subserve this function. Conceptually, then, if leukocytes are primed by LPS, they will produce a much greater oxidative burst when exposed to inflammatory and chemotactic stimuli.
Since LPS also induces a neutrophil adhesion that is probably stronger and certainly more prolonged than that caused by the chemoattractants alone, the net result of LPS exposure is (1) prolonged adhesion to parenchymal cells, and (2) enhanced production of oxygen radicals and proteases.
Together these might be expected to cause enhanced injury.
Early attempts to test this possibility have been encouraging. Bacterial endotoxin is known to produce lung injury in man and many animal systems. However, in rabbits, minute amounts of intravascular LPS (<0.05 ng/ml) act synergistically with neutrophil chemoattractants such as C5 fragments formed from C5 cleavage to induce vascular and epithelial permeability changes in the lung and morphologic evidence of endothelial damage. Neither agent alone at these concentrations produced these effects, and the increased vascular permeability was dependent on the presence of circulating neutrophils. It is important to emphasize that such studies do not exclude the possibility of an additional direct toxic effect of LPS (especially at higher concentrations). Additionally, the interactions are described here to exemplify a phenomenon.
It would be expected that other agents, which induce leukocyte adhesion, priming, and activation, could act similarly. A part of particularly interesting candidates for some of those effects are the peptide interleukin 1 and the phospholipid, platelet activating factor.
These synergistic actions of neutrophils primed with, for example, LPS, and stimulated with chemoattractants have been further pursued in vitro. Cultured endothelial cell monolayers were disrupted (overt cytolysis was the end point) by incubation with these combinations. 12 No 2 of the agents together were effective, and evidence was presented that the effects of the LPS and chemoattractant were exerted predominantly on the neutrophil. In combination with
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MATERIALS AND METHODS

Following injection with saline or antioxidant enzymes (polyethylene glycol [PEG]-attached superoxide dismutase [SOD] and catalase [CAT])
, male Sprague-Dawley rats (350-400 g) were exposed to hyperoxia (>99% Oa, 1 atm) or to normoxia. After 54 hours of exposure, rats were anesthetized (pentobarbital, U0 mg/kg). Tracheostomies and thoracotomies were performed. Following heparin (150 U) administration via the pulmonary artery, catheters were placed and lungs were rapidly perfused blood-free and freezeclamped at liquid nitrogen temperature. Measurement of oxidized and total glutathione in lung tissues was done using recently described tisssue preparation and assay methods. 3 In additional rats' pleural effusion volumes were measured, and lungs were lavaged with saline for measurement of albumin concentrations. 
